These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24695949)

  • 21. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
    Morfini M; Auerswald G; Kobelt RA; Rivolta GF; Rodriguez-Martorell J; Scaraggi FA; Altisent C; Blatny J; Borel-Derlon A; Rossi V
    Haemophilia; 2007 Sep; 13(5):502-7. PubMed ID: 17880436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigating clearance mechanisms for recombinant activated factor VII in a perfused liver model.
    Appa R; Theill C; Hansen L; Møss J; Behrens C; Nicolaisen EM; Klausen NK; Christensen MS
    Thromb Haemost; 2010 Aug; 104(2):243-51. PubMed ID: 20508904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.
    Macik BG; Lindley CM; Lusher J; Sawyer WT; Bloom AL; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):521-7. PubMed ID: 8218848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.
    Morfini M
    Eur J Haematol; 2016 Feb; 96(2):111-8. PubMed ID: 26172449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
    Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
    Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia.
    Spronk HM; Braunschweig T; Rossaint R; Wüst DC; van Oerle R; Lauritzen B; Tolba R; Grottke O
    PLoS One; 2015; 10(6):e0113979. PubMed ID: 26098426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
    Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
    Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery.
    Riddell A; Abdul-Kadir R; Pollard D; Tuddenham E; Gomez K
    Thromb Haemost; 2011 Sep; 106(3):521-7. PubMed ID: 21833443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U; Livnat T; Zivelin A; Kenet G
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
    Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
    Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs.
    Agersø H; Kristensen NR; Østergaard H; Karpf DM; Hermit MB; Pelzer H; Petersen LC; Ezban M
    Eur J Pharm Sci; 2011 Apr; 42(5):578-83. PubMed ID: 21382491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
    Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
    Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
    Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
    Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
    Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.
    Mahlangu JN; Coetzee MJ; Laffan M; Windyga J; Yee TT; Schroeder J; Haaning J; Siegel JE; Lemm G
    J Thromb Haemost; 2012 May; 10(5):773-80. PubMed ID: 22353395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes.
    Yatuv R; Dayan I; Carmel-Goren L; Robinson M; Aviv I; Goldenberg-Furmanov M; Baru M
    Haemophilia; 2008 May; 14(3):476-83. PubMed ID: 18393980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
    Antovic JP; Antovic A; He S; Tengborn L; Blombäck M
    Haemophilia; 2002 Nov; 8(6):781-6. PubMed ID: 12410647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.